Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
124M
-
Shares change
-
-9.03M
-
Total reported value, excl. options
-
$84.2M
-
Value change
-
-$9.62M
-
Put/Call ratio
-
0.05
-
Number of buys
-
72
-
Number of sells
-
-63
-
Price
-
$0.68
Significant Holders of Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) as of Q1 2025
180 filings reported holding NKTR - Nektar Therapeutics - Common Stock, par value $0.0001 per share as of Q1 2025.
Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 124M shares
.
Largest 10 shareholders include BlackRock, Inc. (15.7M shares), VANGUARD GROUP INC (12.3M shares), Nantahala Capital Management, LLC (7.79M shares), ACADIAN ASSET MANAGEMENT LLC (7.3M shares), EVENTIDE ASSET MANAGEMENT, LLC (6.65M shares), PRIMECAP MANAGEMENT CO/CA/ (5.35M shares), RENAISSANCE TECHNOLOGIES LLC (4.7M shares), Almitas Capital LLC (4.61M shares), GEODE CAPITAL MANAGEMENT, LLC (4.01M shares), and TCG Crossover Management, LLC (4M shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.